Rheumatoid Arthritis Disease Progression Modeling.
Time progression models provide a significant advantage in developing clinical trials and can also be used to elicit comparisons among therapeutic agents. The authors performed a meta-analysis to construct a time progression model for rheumatoid arthritis (RA), an area of significant interest for pharmaceutical development, using the ACR20 end point. Compounds studied were chiefly monoclonal antibodies that were used in conjunction with methotrexate. The study shows that an exponential time response model adequately fits the data. From the modeling, a distribution of effects for biological RA therapies can be provided.